The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria for hepatobiliary scintigraphy in abdominal pain.
The document is the third in a series of new appropriate use criteria developed by the society in its role as a qualified provider-led entity under the Medicare Appropriate Use Criteria Program for Advanced Diagnostic Imaging. Technetium-99m-labeled hepatobiliary iminodiacetic acid scintigraphy is used as an adjunct to evaluate patients with abdominal pain.
The organization also has released appropriate use criteria for bone scintigraphy in prostate and breast cancer and also ventilation/perfusion imaging in pulmonary embolism. In addition, criteria for FDG-PET restaging and response assessment of malignant disease have been approved by the SNMMI board and will soon be available online and also published in the Journal of Nuclear Medicine, the society said.
